STX.L Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:24):

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs...

Stats
Today's Volume	3.25M
Average Volume	6.09M
Market Cap	10.36M
EPS	£0 ( 2023-09-28 )
Next earnings date	( £0 ) 2024-04-30
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-0.110
ATR14	£0.0170 (1.29%)

Shield Therapeutics PLC Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shield Therapeutics PLC Financials

Annual	2022
Revenue:	£4.47M
Gross Profit:	£2.00M (44.71 %)
EPS:	£-0.170

Q2	2023
Revenue:	£3.51M
Gross Profit:	£1.42M (40.47 %)
EPS:	£-0.0145

Q4	2022
Revenue:	£2.44M
Gross Profit:	£-428 000 (-17.57 %)
EPS:	£-0.120

Q2	2022
Revenue:	£2.03M
Gross Profit:	£63 000.00 (3.10 %)
EPS:	£-0.0530

Financial Reports:

No articles found.

Shield Therapeutics PLC

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Realtime updates for Shield Therapeutics PLC [STX.L]

Upcoming Earnings Alert